Levodopa

規格

59-92-7CAS番号

200-445-2EC番号

(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acidIUPAC名

C9H11NO4化学式

197.19 g/mol分子量

levodopa; L-dopa; 59-92-7; 3,4-dihydroxy-L-phenylalanine; Dopar; 3-Hydroxy-L-tyrosine; Larodopa; Bendopa; 3-(3,4-Dihydroxyphenyl)-L-alanine; Levopa; Brocadopa; Dopaidan; Dopalina; Dopasol; Eldopal; Insulamina; Pardopa; Cidandopa; Dopaflex; Maipedopa; Deadopa; Eldopar; Prodopa; Syndopa; Veldopa; Helfo-Dopa; (-)-Dopa; Doparkine; Dopastral; Dopaston; Doparl; Doprin; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; Dihydroxy-L-phenylalanine; Eldopatec; Eurodopa; L-3,4-Dihydroxyphenylalanine; Ledopa; L-o-Hydroxytyrosine; L-Tyrosine, 3-hydroxy-; Biodopa; Levodopum; (-)-3-(3,4-Dihydroxyphenyl)-L-alanine; Dopaston SE; 3,4-Dihydroxyphenyl-L-alanine; Helfo DOPA; Laradopa; Sobiodopa; Cerepap; Parda; beta-(3,4-Dihydroxyphenyl)-L-alanine; L-(-)-Dopa; L-Dihydroxyphenylalanine; L-beta-(3,4-Dihydroxyphenyl)alanine; Inbrija; Ro 4-6316; L Dopa; L-O-Dihydroxyphenylalanine; CVT-301; beta-(3,4-Dihydroxyphenyl)alanine; alanine, 3-(3,4-dihydroxyphenyl)-, L-; DTXSID9023209; L(-)-Dopa; beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine; L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine; Alanine, 3-(3,4-dihydroxyphenyl)-, (-)-; NSC-118381; CHEBI:15765; beta-(3,4-Dihydroxyphenyl)-alpha-alanine; NSC118381; DHIVY COMPONENT LEVODOPA; DTXCID303209; DUOPA COMPONENT LEVODOPA; RYTARY COMPONENT LEVODOPA; 46627O600J; CREXONT COMPONENT LEVODOPA; STALEVO COMPONENT LEVODOPA; CORBILTA COMPONENT LEVODOPA; V-1512; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate; LEVODOPA/CARBIDOPA/ENTACAPONE ORION COMPONENT LEVODOPA; 3 Hydroxy L tyrosine; L 3,4 Dihydroxyphenylalanine; L-Dopa Phenolic; RefChem:6454; L DOPA 4X; L-Dopa 1514; N04BA01; (--)-3-(3,4-Dihydroxyphenyl)-L-alanine; (--)-2Amino-3-(3,4-dihydroxyphenyl)propanoic Acid; 200-445-2; (2S)-2-azaniumyl-3-(3,4-dihydroxyphenyl)propanoate; Dopa; 3,4-Dihydroxyphenylalanine; Dopal-fher; Levedopa; L-(o-Dihydroxyphenyl)alanine; Weldopa; L-3-(3,4-Dihydroxyphenyl)alanine; MFCD00002598; (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; L-3-Hydroxytyrosine; component of Sinemet; Dopar (TN); (-)-(3,4-Dihydroxyphenyl)alanine; L-.beta.-(3,4-Dihydroxyphenyl)alanine; CHEMBL1009; .beta.-(3,4-Dihydroxyphenyl)-L-alanine; L-(3,4-Dihydroxyphenyl)alanine; .beta.-(3,4-Dihydroxyphenyl)alanine; CAS-59-92-7; NCGC00016270-04; L-(3,4-Dihydroxyphenyl)-.alpha.-alanine; Phenylalanine, 3,4-dihydroxy-; Atamet; Levodopum [INN-Latin]; BDBM50130192; 65170-01-6; L-3; CCRIS 3766; HSDB 3348; WLN: QVYZ1R CQ DQ; 3,4-Dihydroxyphenylalanine (VAN); SR-01000075384; EINECS 200-445-2; NSC 118381; L-3,4-Dihydrophenylalanine; Dopastone; Dopicar; Prolopa; Brocadopa;; Larodopa;; Bendopa;; Levodopa RS; Levopa;; Levodopa CRS; Dopar;; UNII-46627O600J; Prestwick_185; Levodopa (Sinemet); L-DOPA; Levodopa; Madopa (Salt/Mix); Levodopa [USAN:USP:INN:BAN:JAN]; L-DOPA (Standard); Spectrum_000454; 4-dihydroxyphenylalanine; LEVODOPA [HSDB]; LEVODOPA [USAN]; LEVODOPA [INN]; LEVODOPA [JAN]; LEVODOPA [MI]; LEVODOPA [VANDF]; Prestwick0_000017; Prestwick1_000017; Prestwick2_000017; Prestwick3_000017; Spectrum2_000496; Spectrum4_000539; Spectrum5_001899; Lopac-D-9628; Levodopa (JP15/USP); LEVODOPA [MART.]; bmse000322; Epitope ID:150927; LEVODOPA [USP-RS]; LEVODOPA [WHO-DD]; LEVODOPA [WHO-IP]; DOPA, L-; 3, 4-Dihydroxyphenylalanine; Alanine,4-dihydroxyphenyl)-; LEVODOPA [EMA EPAR]; Lopac0_000454; SCHEMBL22655; BSPBio_000053; BSPBio_002354; KBioGR_001177; KBioSS_000934; L-4-5-Dihydroxyphenylalanine; MLS000028514; BIDD:GT0158; DivK1c_000452; SPECTRUM2300205; Levodopa (JP18/USP/INN); SPBio_000391; SPBio_001974; LEVODOPA [EP IMPURITY]; LEVODOPA [ORANGE BOOK]; BPBio1_000059; GTPL3639; orb1310238; orb3141124; SCHEMBL3857245; LEVODOPA [EP MONOGRAPH]; b-(3,4-Dihydroxyphenyl)alanine; LEVODOPA [USP MONOGRAPH]; SCHEMBL29373537; WLN: QVYZ1R CQ DQ -L; 3, 4-Dihydroxy-L-phenylalanine; BDBM60928; HMS501G14; HY-N0304R; KBio1_000452; KBio2_000934; KBio2_003502; KBio2_006070; PARCOPA COMPONENT LEVODOPA; LEVODOPUM [WHO-IP LATIN]; MSK1487; Alanine,4-dihydroxyphenyl)-, L-; CARBILEV COMPONENT LEVODOPA; CHEBI:233994; DOPASNAP COMPONENT LEVODOPA; IPX203 COMPONENT LEVODOPA; L-(3, 4-Dihydroxyphenyl)alanine; NINDS_000452; GLXC-07334; HMS1568C15; HMS1922J14; HMS2090O08; HMS2093N04; HMS2095C15; HMS2230B04; HMS3261K10; HMS3712C15; Pharmakon1600-02300205; HY-N0304; IPX-203 COMPONENT LEVODOPA; Levodopa;3,4-Dihydroxyphenylalanine; b-(3,4-Dihydroxyphenyl)-L-alanine; Inbrija (levodopa inhalation powder); LEVODOPA COMPONENT OF PARCOPA; LEVODOPA COMPONENT OF SINEMET; Tox21_110338; Tox21_500454; CCG-39571; EBC-12565; HB1925; L-3-(3,4-dihydroxy-phenyl)alanine; L-3-(3,4-dihydroxyphenyl)-Alanine; NSC759573; PDSP1_001541; PDSP2_001525; s1726; SBB017533; Alanine, 3-(3,4-dihydroxyphenyl)-; Alanine,4-dihydroxyphenyl)-, (-)-; LEVODOPA COMPONENT OF CARBILEV; AKOS010396267; b-(3,4-Dihydroxyphenyl)-a-L-alanine; L-b-(3,4-Dihydroxyphenyl)-a-alanine; L-DOPA (3,4-Dihydroxyphenylalanine); .beta.-(3, 4-Dihydroxyphenyl)alanine; AC-8432; CS-1945; DB01235; FD15635; LP00454; NSC-759573; SDCCGMLS-0066924.P001; SDCCGSBI-0050439.P004; IDI1_000452; NCGC00015384-01; NCGC00016270-01; NCGC00016270-06; NCGC00016270-07; NCGC00016270-09; NCGC00016270-10; NCGC00016270-16; NCGC00016270-22; NCGC00093869-04; NCGC00261139-01; AS-13287; BP-12850; SMR000058312; ST086623; SY010977; SBI-0050439.P003; L-(3, 4-Dihydroxyphenyl)-.alpha.-alanine; D0600; D9628; EU-0100454; L1782; NS00068395; 2-Amino-3-(3,4-dihydroxyphenyl)propanoicacid; EN300-52637; Alanine, 3-(3, 4-dihydroxyphenyl)-, (-)-; C00355; D 9628; D00059; D70595; 3,4-Dihydroxy-L-phenylalanine, >=98% (TLC); AB00052418-06; AB00052418-07; AB00052418_08; AB00052418_09; F358380; Q300989; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoicacid; SR-01000075384-1; SR-01000075384-4; SR-01000075384-6; SR-01000075384-7; (S)-2-Amino-3-(3,4-dihydroxyphenyl) propanoic acid; BRD-K34730807-001-15-0; BRD-K34730807-001-16-8; BRD-K34730807-001-17-6; (S)-2-Amino-3-(3,4-dihydroxy-phenyl)-propionic acid; F0347-4695; Levodopa Working Standard (Secondary Reference Standard); Levodopa, British Pharmacopoeia (BP) Reference Standard; Levodopa, European Pharmacopoeia (EP) Reference Standard; Z756440064; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acidL-dopa; 1E83F927-C221-46AA-B90A-81B33C5F3868; 3,4-Dihydroxy-L-phenylalanine, Vetec(TM) reagent grade, 98%; Levodopa, United States Pharmacopeia (USP) Reference Standard; 3,4-Dihydroxy-L-phenylalanine, certified reference material, TraceCERT(R); Levodopa, Pharmaceutical Secondary Standard; Certified Reference Material; 122769-74-8別名